Search filters

List of works by Keith D Wilner

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

scientific article

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

scientific article

Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers

scientific article published in January 2006

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

scientific article

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

scientific article published on 04 September 2012

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

scientific article

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

scientific article

CP-101,606: An NR2B-Selective NMDA Receptor Antagonist

scientific article published in December 1998

Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers

scientific article (publication date: September 2002)

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

scientific article published on 26 January 2015

Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer

scientific article

Complex renal cysts associated with crizotinib treatment

scientific article published on 10 March 2015

Crizotinib Versus Chemotherapy in Asian Patients with Advanced ALK-positive Non-small Cell Lung Cancer.

scientific article published on 06 July 2017

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

scientific article

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

scientific article

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

scientific article

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

scientific article

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007).

scientific article published on 28 January 2016

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014.

scientific article

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

scientific article

Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in the Japanese population

scientific article published on 22 September 2020

Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma

scientific article published on 22 April 2013

Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials

scientific article published on 14 March 2017

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

scientific article

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

scientific article published on 31 October 2011

National Working Group Meeting on ALK diagnostics in lung cancer.

scientific article

Network meta-analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival

scientific article published on 01 September 2020

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer

scientific article

Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer

scientific article published in November 2014

Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission

scientific article published in August 2003

Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers

scientific article published in June 2005

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

scientific article published on 9 March 2010

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer ⬇️

scientific article published on November 16, 2011

ROS1 rearrangements define a unique molecular class of lung cancers

scientific article

Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor ⬇️

scientific article published on December 12, 2011

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer

scientific article published on December 2010

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

scientific article

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

scientific article

Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents

scientific article published on June 2006

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study

scientific article published on 8 August 2017

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers ⬇️

scientific article published on October 28, 2010

The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery

scientific article published in April 2002

The effect of food on the absorption of oral ziprasidone.

scientific article

The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil

scientific article published on January 2002

The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers

scientific article published on January 2002

Treatment of growing teratoma syndrome

scientific article published in January 2009

Paulina is supported by:

About Paulina

Help